This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.
Also contributing to the predicted market growth are recent product approvals such as Takeda's Takecab (vonoprazan) for gastroesophageal reflux disease, and Entvio (vedolizumab) for IBD.
vedolizumab. Entyvio. Takeda. Ulcerative Colitis and Crohn's Disease. sacubitril/ valsartan. Entresto.
Takeda has high hopes for ixazomib, billing it as the company's second 'global launch' after ulcerative colitis therapy Entyvio (vedolizumab) - in other words a product that it will launch not
NICE has recommended Entyvio (vedolizumab) to treat moderate to severe ulcerative colitis in final draft guidance. ... Vedolizumab works in a different way to other treatment options [by] targeting the immune system in the gut rather than the whole body
Professor Carole Longson, director of NICE's health technology evaluation centre, said: “ Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when
These include the recently-approved Entyvio (vedolizumab) for Crohn's disease and ulcerative colitis, ixazomib (MLN9708) for multiple myeloma and alisertib (MLN8237) for peripheral T cell lymphoma.
More from news
Approximately 8 fully matching, plus 10 partially matching documents found.
There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.